Clinical trials: Locally Advanced or
- Condition Locally Advanced or
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT06902545
- Testing
- zolbetuximab
- Where
- 15 sites in South Korea
- Volunteers
- 377 people
- Sponsor
- Astellas Pharma Korea, Inc.
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
Malignant Melanoma
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in participants with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF…
- Trial name
- NCT01586195
- Testing
- Vemurafenib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Soft Tissue Sarcoma
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
This is a Phase 2, single-arm, Japanese multicenter trial to evaluate the safety, tolerability, and efficacy of TH-302 in combination with doxorubicin in subjects with locally advanced unresectable or metastatic soft tissue…
- Trial name
- NCT02255110
- Testing
- TH-302, Doxorubicin
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Locally Advanced Unresectable or Metastatic Gastric Cancer
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer…
- Trial name
- NCT07547787
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Akeso
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
- Trial name
- NCT02049905
- Testing
- Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 433 people
- Sponsor
- ImmunityBio, Inc.
Non Small Cell Lung Cancer
A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).
The primary objective of the study is to collect epidemiological data on EGFR mutation status [M+(mutation positive), M-(mutation negative)] in a population of predominantly Caucasian ethnicity, and to correlate EGFR mutation…
- Trial name
- REASON (NCT01153399)
- Where
- 9 sites in Greece
- Volunteers
- 589 people
- Sponsor
- AstraZeneca
Colorectal Neoplasms
Stivarga Regulatory Post-Marketing Surveillance Study in Korea
To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.
- Trial name
- StivargaPMS (NCT02106858)
- Testing
- Regorafenib (Stivarga,BAY73-4506)
- Where
- South Korea
- Volunteers
- 316 people
- Sponsor
- Bayer
Non-Small Cell Lung Cancer
Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion
This observational study evaluates the real-world safety and effectiveness of repotrectinib in Korean participants with locally advanced or metastatic ROS1-positive non-small cell lung cancer or solid tumors harboring…
- Trial name
- NCT07599007
- Testing
- Repotrectinib
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult…
- Trial name
- TRIDENT-1 (NCT03093116)
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 500 people
- Sponsor
- Turning Point Therapeutics, Inc.
Colorectal Cancer, Non-Small Cell Lung Cancer
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in…
- Trial name
- ARIES (NCT00388206)
- Volunteers
- 3,998 people
- Sponsor
- Genentech, Inc.
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion, Infantile Fibrosarcoma
A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database
This is an observational study in which data from the past of children and young people with a specific cancer, called NTRK gene fusion positive infantile fibrosarcoma (IFS) is studied.
- Trial name
- EPI VITRAKVI (NCT05236257)
- Testing
- Larotrectinib (Vitrakvi, BAY2757556), Standard of Care
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Bayer
Gastric Adenocarcinoma
A Real World Study of the Treatment of Gastric Adenocarcinoma With Huachansu
To evaluate the efficacy and safety of huachansu oral preparation in the treatment of inoperable locally advanced or advanced metastatic gastric adenocarcinoma, including gastric esophageal adenocarcinoma.
- Trial name
- NCT05249244
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
- Trial name
- NCT04094610
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- Turning Point Therapeutics, Inc.
Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
This is a phase 2b, randomized, open-label, prospective, multicenter study comparing treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been…
- Conditions
- Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
- Trial name
- NCT01514188
- Testing
- INNO-206, Doxorubicin
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 126 people
- Sponsor
- ImmunityBio, Inc.
Synovial Sarcoma, Soft Tissue Sarcoma
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic…
- Trial name
- NCT05355753
- Testing
- CFT8634
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- C4 Therapeutics, Inc.
Soft Tissue Sarcoma
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma.
- Trial name
- NCT01440088
- Testing
- TH-302 in Combination with Doxorubicin, Doxorubicin
- Where
- 92 sites in United States, Austria and 11 more
- Volunteers
- 640 people
- Sponsor
- Threshold Pharmaceuticals
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced…
- Trial name
- NCT05384626
- Testing
- Neladalkib (NVL-655), Midazolam, Repaglinide
- Where
- 74 sites in United States, Australia and 13 more
- Volunteers
- 840 people
- Sponsor
- Nuvalent Inc.
Colorectal Cancer
A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable colorectal cancer who are receiving Avastin in combination with chemotherapy and whose cancer has been either…
- Trial name
- NCT00097578
- Where
- United States
- Volunteers
- 1,953 people
- Sponsor
- Genentech, Inc.
Advanced or Metastatic Liposarcoma or Leiomyosarcoma
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
The purpose of this study is to find the optimal dose of trabectedin for Chinese patients with locally advanced or metastatic L-sarcoma (liposarcoma or leiomyosarcoma) who were previously treated (in any order) with at least an…
- Trial name
- NCT01692678
- Testing
- Trabectedin, Dacarbazine
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.